Table 1.
Patients' characteristics
| No. | Sex | Age | Myeloma type | Disease duration (months) | M gradient (g/l) | FLC (mg/l) | BM involvement (%) | Previous therapies |
|---|---|---|---|---|---|---|---|---|
| 1 | m | 76 | IgG κ | PD | 3.4 | 4440 (κ) | 40 | none |
| 2 | f | 64 | Plasmocytoma λ | PD | 0 | 9.0 (λ) | 0 | none |
| 3 | f | 65 | IgA κ | PD | 0 | 233 (κ) | 30 | none |
| 4 | f | 65 | IgA κ | 3 | 0 | 498 (κ) | 50 | CTx |
| 5 | m | 64 | IgG κ | 4 | 51.1 | 293 (κ) | 40 | CTx |
| 6 | f | 60 | IgG κ | 120 | 16.2 | 1237 (κ) | n/a | CTx, Auto-Tx |
| 7 | m | 54 | IgA κ | PD | 41.3 | 11.6 (κ) | 70 | none |
| 8 | f | 56 | IgA λ | PD | n/a | 345 (λ) | 25 | none |
| 9 | m | 60 | IgA λ | 9 | 3.5 | 2525 (λ) | 90 | CTx, Auto-Tx |
| 10 | m | 82 | IgA κ | 55 | n/a | 23.0 (κ) | n/a | CTx, |
| 11 | m | 67 | IgG λ | 15 | n/a | 15.7 (κ) | 5 | CTx, Auto-Tx |
| 12 | m | 59 | light chain κ | 7 | 3.4 | n/a | n/a | RTx |
| 13 | m | 48 | IgG κ | PD | 58.9 | 48.0 (κ) | n/a | none |
| 14 | m | 70 | IgG κ | 103 | 23.2 | 8833 (κ) | n/a | CTx, Auto-Tx |
| 15 | f | 69 | IgG κ | 10 | 26.4 | 687 (κ) | n/a | CTx, Auto-Tx |
| 16 | f | 63 | light chain κ | 32 | 0 | 3079 (κ) | n/a | CTx, Auto-Tx |
| 17 | f | 74 | IgG λ | PD | 31.9 | 337 (λ) | n/a | none |
| 18 | f | 64 | IgA κ | 6 | 0 | 27,4 (κ) | 0 | CTx; Auto-Tx |
| 19 | m | 56 | IgA κ | 32 | 44.7 | 0.5 (κ) | 50 | CTx, Auto-Tx |
| 20 | f | 62 | IgG κ | 11 | 24.4 | 254.3 (κ) | 15 | CTx |
| 21 | m | 63 | light chain κ | PD | 1.9 | 14014 (κ) | 70 | none |
| 22 | f | 48 | IgA λ | 63 | 6 | 177.7 (λ) | 3 | CTx, Auto-Tx |
| 23 | m | 51 | IgG κ | 34 | 24.6 | 828.0 (κ) | 60 | CTx, Auto-Tx |
| 24 | m | 47 | light chain κ | PD | 0 | 904.9 (κ) | 90 | none |
| 25 | m | 62 | light chain λ | PD | 1.8 | 444.0 (λ) | 15 | none |
| 26 | m | 59 | IgG κ | 37 | 0 | 5.0 (κ) | 0 | CTx, Auto-Tx |
| 27 | m | 59 | IgG κ | 4 | 26.3 | 551.2 (κ) | 40 | CTx |
| 28 | m | 65 | IgG κ | 89 | 10.4 | 37.8 (κ) | n/a | CTx, Auto-Tx |
| 29 | f | 65 | IgA κ | 12 | 0 | 2387 (κ) | 90 | CTx, Auto-Tx |
| 30 | f | 39 | IgG λ | 58 | 31.0 | 97.5 (λ) | n/a | CTx, Auto-Tx |
| 31 | f | 68 | IgG λ | 31 | 29.8 | 1673 (λ) | 35 | CTx, Auto-Tx |
| 32 | m | 73 | IgG κ | 72 | 4.7 | 25100 (κ) | 70 | CTx, Auto-Tx |
| 33 | m | 62 | IgG κ | 199 | 13.0 | 14015 (κ) | 20 | CTx, Auto-Tx |
| 34 | m | 62 | light chain λ | 47 | 0 | 240.8 (λ) | 5 | CTx, Auto-Tx |
| 35 | m | 72 | IgG λ | PD | 35.4 | 5297 (λ) | 90 | none |
| 36 | f | 53 | light chain κ | 122 | 0 | 99.0 (κ) | 15 | CTx, Auto-Tx |
| 37 | m | 63 | light chain λ | 6 | 0 | 12.4 (λ) | 0 | CTx |
| 38 | f | 63 | IgG κ | 22 | 47.5 | 1907 (κ) | 30 | CTx, Auto-Tx |
| 39 | m | 63 | IgG κ | 86 | 4.1 | 535.0 (κ) | n/a | CTx, Auto-Tx |
| 40 | m | 60 | light chain λ | 22 | 0 | 124.2 (λ) | 20 | CTx, Auto-Tx |
| 41 | f | 63 | light chain λ | 23 | 0 | 1876 (λ) | 10 | CTx, Auto-Tx |
| 42 | f | 49 | IgA λ | 72 | 0 | 30.8 (λ) | 0 | CTx, Auto-Tx |
| 43 | f | 40 | light chain κ | 39 | 0 | 50.0 (κ) | n/a | CTx, Auto-Tx |
m = male. f = female. Disease duration is given in months. PD = primary diagnosis. CTx = chemotherapy including novel agents, RTx = radiotherapy. Auto-Tx = autologous stem cell transplantation. n/a = information not available